Meet us in Boston at the DIA Annual Meeting

We are eagerly anticipating the DIA 2023 Global Annual Meeting in Boston, MA next week! We will be showcasing our wearable sensors and digital health technologies for monitoring motor, speech and cognitive functions, as well as mental health. These validated technologies are used in clinical trials and research in many therapeutic areas, ranging from neurological disorders to cancer and respiratory diseases. 

Please visit booth #266 to see our validated products for measurement of digital biomarkers in neurological and neuromuscular disorders, including:

• LEGSys and BalanSens: The first FDA-registered wearable devices for clinical gait and balance assessments. The devices have been used in 200+ clinical studies and trials, including the measurements of primary endpoints in 15+ clinical trials.
  

• PAMSys: The most advanced wearable sensor for precision actigraphy, including continuous monitoring of walking parameters, posture and postural transition, sedentary behavior, sleep and sleep quality, and falls during activities of daily living. PAMSys measures 40+ independent parameters of physical activity and has been used in 10+ clinical trials for collecting secondary and primary endpoints. 
  

• BioDigit Home: The most comprehensive solution for the measurement of digital biomarkers in neurological and neuromuscular disorders. BioDigit Home includes over 100 digital assessments of motor, cognition, and speech functions, as well as mental health and complete ePRO/eCOA capabilities.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of its solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.